Check-Cap Ltd (NASDAQ:MBAI) Short Interest Update

Check-Cap Ltd (NASDAQ:MBAI) was the target of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 26,875 shares, a decrease of 71.9% from the July 30th total of 95,679 shares. Approximately 2.0% of the company’s stock are sold short. Based on an average daily trading volume, of 27,346 shares, the days-to-cover ratio is currently 1.0 days.

Check-Cap Stock Down 3.1%

Shares of NASDAQ:MBAI traded down $0.21 during midday trading on Thursday, reaching $6.57. The company’s stock had a trading volume of 14,919 shares, compared to its average volume of 144,859. The stock has a fifty day moving average of $8.22 and a 200 day moving average of $10.45. Check-Cap has a twelve month low of $4.35 and a twelve month high of $27.44. The firm has a market capitalization of $9.03 million, a PE ratio of -0.47 and a beta of 0.68.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

About Check-Cap

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.